



Terns Pharmaceuticals to Participate in the Cowen 42nd Annual Healthcare Conference

February 28, 2022

FOSTER CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases, such as NASH and obesity, today announced that management will be participating in a NASH discussion panel at the Cowen 42nd Annual Healthcare Conference on Tuesday, March 8 at 12:50pm ET.

A live webcast of the event will be available on the investor relations page of the Terns Pharmaceuticals website at <http://ir.ternspharma.com>. A replay of the webcast will be archived on Terns' website for 30 days following the presentation.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases, such as NASH and obesity. Terns' pipeline includes three clinical stage development programs including an FXR agonist, a VAP-1 inhibitor and a THR- β agonist, and a preclinical GLP-1 receptor agonist program. Terns is focused on developing combination therapies based on clinically validated and complementary mechanisms of action to drive meaningful clinical benefits for patients. For more information, please visit: www.ternspharma.com.

Contacts for Terns

Investors

Justin Ng

investors@ternspharma.com

Media

Jenna Urban

Berry & Company Public Relations

media@ternspharma.com